The bill introduced on March 20, 2025, aims to amend the Code of West Virginia regarding the scheduling of controlled substances. It proposes the addition of several new substances to Schedule I, including Brorphine and a defined term for "fentanyl analog or derivative," while maintaining fentanyl and carfentanil as Schedule II substances. The bill also introduces new entries such as 1-(4-methoxyphenyl)-N-methylpropan-2-amine and 2-Methyl AP-237, reflecting the need to adapt to emerging drug trends. Additionally, it seeks to correct errors in the existing code, including the removal of Norfentanyl from Schedule I, thereby enhancing public safety through updated classifications.

Further amendments include the addition of new substances to Schedule IV and Schedule V, with notable inclusions such as Alfaxalone, Daridorexant, Zuranolone, and Ganaxolone. The bill also aims to streamline the legal framework by deleting outdated or incorrect language, although specific deletions are not detailed. Overall, the legislation seeks to ensure that the classifications of controlled substances are accurate and current, thereby improving regulatory measures against synthetic drugs and enhancing public health and safety.

Statutes affected:
Introduced Version: 60A-2-204, 60A-2-206, 60A-2-208, 60A-2-210, 60A-2-212